(CELG - Get Report) hasn't yet announced results from the Abraxane phase III study in pancreatic cancer but the drug generated a lot of positive buzz at this weekend's European Society of Medical Oncology (ESMO) conference.
Cancer consultant guru and blogger Sally Church, in attendance at ESMO, notes oncologists who specialize in pancreatic cancer are typically a dour lot because of the paucity of effective therapies at their disposal. But she was surprised to see these experts in an "excited and feisty mood" Friday because of Abraxane data expected very soon.
On the timing of Celgene announcing results from the Abraxane phase III study, Church
"While it was made abundantly clear by the panel that the final data isn't yet available, all of the KOLs
key opinion leaders
presenting were at pains to say in their presentations it will be in a "few weeks" or "very soon" so thankfully we won't have long to wait for the press release."
Furthermore, Abraxane sentiment is positive. Again,
"My assumption though, is that the nab-paclitaxel
is positive since a first cut of the analysis could be available by now, especially if the data will be announced soon. Why else would there be such warm enthusiasm from a well-respected panel?"
Pieter Droppert, Church's colleague and fellow blogger, put together a Storify
aggregating Abraxane-related tweets
from ESMO 2012 and notes that chatter about the drug overshadowed the presentation of actual pancreatic cancer data from
(THLD - Get Report)
The best way for investors to play the coming Abraxane data is to buy the
Celgene contingent value right
created by Celgene when it acquired Abraxane's original owner Abraxis BioScience in 2010, says hedge fund manager and
contributor Jim Silverman.
"What I like about the
is the potential for a nearly $7.50-per-share payout should a phase III study of Abraxane in pancreatic cancer succeed," Silverman
wrote in a column last week
The Celgene CVR rose 10% on Friday to close at 2.83 per share.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts